Aptel Florent, Bron Alain M, Lachkar Yves, Schweitzer Cédric
*Department of Ophthalmology, University Hospital of Grenoble, Grenoble †Department of Ophthalmology, University Hospital of Dijon, Dijon ‡Institut du Glaucome, Fondation Hôpital Saint-Joseph, Paris §Department of Ophthalmology, CHU Bordeaux ∥Bordeaux Population Health Research Center, Team LEHA, University Bordeaux, Inserm, Bordeaux, France.
J Glaucoma. 2017 Oct;26(10):875-880. doi: 10.1097/IJG.0000000000000748.
To evaluate the effect of treatment escalation on the rate of visual field progression in patients with primary open-angle glaucoma (POAG).
Multicenter database study. We reviewed the electronic records of 171 patients with POAG under medical hypotensive treatment who underwent 5 consecutive visits 6 months apart before and after medical treatment escalation or additive laser trabeculoplasty. We calculated the rate of visual field progression (mean deviation change per year) before and after treatment escalation.
The mean duration of follow-up was 5.1±0.5 years and the mean number of visual field examinations was 10.2±0.2. In 139 eyes with medical treatment escalation, the rate of progression was significantly reduced [from -0.57 to -0.29 dB/y; P=0.022; intraocular pressure (IOP) reduction 11.1%]. In detail, the rate of progression was significantly reduced after escalation from mono to dual therapy, dual to triple therapy, and from mono to triple therapy (-0.35 to -0.24 dB/y, P=0.018; -1.01 to -0.48 dB/y, P=0.038; -1.04 to -0.35 dB/y, P=0.020, respectively). In 32 eyes with additive laser trabeculoplasty, the rate of progression was significantly reduced (-0.60 to -0.24 dB/y; P=0.014; IOP reduction 9.4%).
Medical treatment escalation or additive laser trabeculoplasty significantly reduced the rate of visual field progression in POAG. Larger IOP reduction has a greater probability of reducing glaucoma progression.
评估治疗升级对原发性开角型青光眼(POAG)患者视野进展速度的影响。
多中心数据库研究。我们回顾了171例接受降压治疗的POAG患者的电子记录,这些患者在药物治疗升级或辅助激光小梁成形术前后,每隔6个月连续进行了5次就诊。我们计算了治疗升级前后视野进展的速度(每年平均偏差变化)。
平均随访时间为5.1±0.5年,平均视野检查次数为10.2±0.2次。在139只接受药物治疗升级的眼中,进展速度显著降低[从-0.57降至-0.29dB/y;P=0.022;眼压(IOP)降低11.1%]。详细而言,从单药治疗升级为联合治疗、联合治疗升级为三联治疗以及从单药治疗升级为三联治疗后,进展速度均显著降低(分别为-0.35至-0.24dB/y,P=0.018;-1.01至-0.48dB/y,P=0.038;-1.04至-0.35dB/y,P=0.020)。在32只接受辅助激光小梁成形术的眼中,进展速度显著降低(-0.60至-0.24dB/y;P=0.014;IOP降低9.4%)。
药物治疗升级或辅助激光小梁成形术显著降低了POAG患者的视野进展速度。更大程度的眼压降低有更大的概率减少青光眼进展。